Delta-Fly Pharma (4598) Reports Earnings: Operating Loss of 420 Million Yen

Delta-Fly Pharma Inc. (4598) has released its latest financial results, reporting an operating loss of 420 million yen, ordinary loss of 422 million yen, and a net loss of 422 million yen, with basic earnings per share (EPS) at -30.23 yen. As a research-and-development-driven biotech venture, ongoing investments in pipeline development continue to impact near-term profitability.

Regarding the financial position and cash flows, cash and cash equivalents stood at 0.15 billion yen, while operating cash flow recorded -1.56 billion yen. As of June 30, 2026, the company reported an equity ratio of -131.8% and retained earnings of approximately -11.980 billion yen, indicating that financial soundness and future capital management strategies remain key focus areas for investors monitoring the progress of its biopharmaceutical portfolio.

---

Correction (September 19, 2026)：The affected figures and reporting-period labels were corrected after checking the source disclosure. Source disclosure